RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up

Abstract

Multiple laser systems for the treatment of benign prostatic hyperplasia (BPH) have been introduced. Current laser systems have limitations due to their laser physics. The RevoLix laser combines the advantages of the Holmium:YAG laser with the comfort of a continuous wave (cw) laser beam. This study reports the preliminary results of vaporesection (simultaneous vaporization and resection) of the prostate, using the 2 microm cw laser. A total of 54 consecutive patients were treated with the 70 W RevoLix laser for BPH. The mean age was 61 years. Mean prostate volume was 30.3 cc. A 550 microm RigiFib bare-ended fiber was used in combination with a 26 French laser resectoscope. Measured outcomes were resection time, decrease in hemoglobin and transfusion rate. Furthermore, the catheter time, improvement in the urinary flow rate (Q(max)), post-voiding residual urine (PVR), International Prostate Symptom Score (IPSS) and Quality of Life Index (QoL) were recorded. Average resection time was 52 min. After crossing the learning curve, a tissue ablation of 1.5 g/min was possible. Transfusions were not necessary in any patient. Catheter time was 1.7 days. Q(max) significantly improved from 4.2 to 20.1 ml on average. PVR decreased from 86 to 12 ml. IPSS and QoL-Score improved from 19.8 to 6.9 and 4 to 1, respectively. No patient required re-hospitalization. These preliminary results indicate that RevoLix vaporesection of the prostate is safe and efficient. One-year follow-up data showed a significant improvement in voiding symptoms and patients' quality of life. A longer follow-up is needed to prove the durability of these promising results.